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Abstract
Objectives To investigate if quantitative apparent diffusion coefficient (ADC)measurements can predict genetic subtypes of non-
gadolinium-enhancing gliomas, comparing whole tumour against single slice analysis.
Methods Volumetric T2-derived masks of 44 gliomas were co-registered to ADC maps with ADC mean (ADCmean) calculated.
For the slice analysis, two observers placed regions of interest in the largest tumour cross-section. The ratio (ADCratio) between
ADCmean in the tumour and normal appearing white matter was calculated for both methods.
Results Isocitrate dehydrogenase (IDH) wild-type gliomas showed the lowest ADC values throughout (p < 0.001). ADCmean in
the IDH-mutant 1p19q intact group was significantly higher than in the IDH-mutant 1p19q co-deleted group (p < 0.01). A
volumetric ADCmean threshold of 1201 × 10
−6 mm2/s identified IDHwild-type with a sensitivity of 83% and a specificity of 86%;
a volumetric ADCratio cut-off value of 1.65 provided a sensitivity of 80% and a specificity of 92% (area under the curve (AUC)
0.9–0.94). A slice ADCratio threshold for observer 1 (observer 2) of 1.76 (1.83) provided a sensitivity of 80% (86%), specificity of
91% (100%) and AUC of 0.95 (0.96). The intraclass correlation coefficient was excellent (0.98).
Conclusions ADCmeasurements can support the distinction of glioma subtypes. Volumetric and two-dimensional measurements
yielded similar results in this study.
Key Points
• Diffusion-weighted MRI aids the identification of non-gadolinium-enhancing malignant gliomas
• ADC measurements may permit non-gadolinium-enhancing glioma molecular subtyping
• IDH wild-type gliomas have lower ADC values than IDH-mutant tumours
• Single cross-section and volumetric ADC measurements yielded comparable results in this study
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Abbreviations
ADC Apparent diffusion coefficient
AUC Area under the curve
CS Centrum semiovale
DKI Diffusion kurtosis imaging
DTI Diffusion tensor imaging
DWI Diffusion-weighted imaging
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IDHwt Isocitrate dehydrogenase wild-type
IDHmut1p19int Isocitrate dehydrogenase-mutant 1p19q
intact
IDHmut1p19del Isocitrate dehydrogenase-mutant 1p19q co-
deleted
ICC Intraclass correlation coefficient
LGG Low grade glioma
NAWM Normal appearing white matter
PACS Picture archiving and communications
system
ROC Receiver operating characteristic
ROICS Centrum semiovale region of interest
ROItum Tumour region of interest
TE Echo time
TR Repetition time
VOICS Centrum semiovale volume of interest
VOItum Tumour volume of interest
WHO World Health Organization
2HG D2-hydroxyglutarate
Introduction
Gadolinium contrast uptake was previously considered the
best MR imaging predictor of glioma histological grade and
malignancy[1–3]. On the basis of this, it has been common
practice to interpret non-enhancing intrinsic tumours as prob-
able low grade gliomas (LGG) [4]. But conventional MRI has
proven to be unreliable in predicting subsequent tumour be-
haviour, whereby a proportion of presumed LGGmay rapidly
progress with development of malignant features such as en-
hancement and necrosis [4–8].
The discovery of several key genetic alterations as princi-
pal determinants of glioma prognosis has challenged the ref-
erence standard of glioma grouping by histology [9].
Mutations in isocitrate dehydrogenase (IDH) represent a com-
mon (> 70%) defining event in the development of LGG,
conversely more than 90% of glioblastomas belong to the
IDH wild-type group [10, 11]. Despite its oncogenic effect
t h rough produc t i on o f a tox i c me tabo l i t e D2-
hydroxyglutarate (2HG), the presence of an IDH mutation is
associated with a favourable prognosis.
The revised 2016 World Health Organization (WHO) clas-
sification of brain tumours for the first time incorporates mo-
lecular data to augment the diagnosis [12]. ForWHO grade II/
III gliomas, three molecular subgroups have been defined:
IDH wild-type glioma (IDHwt) with survival similar to that
of glioblastoma, IDH-mutant glioma with intact 1p19q
(IDHmut1p19int) and an intermediate prognosis, and IDH-
mutant 1p19q co-deleted glioma (IDHmut1p19qdel) with the
best prognosis and greatest chemosensitivity [11]. There is
partial overlap with histomorphology, whereby many
IDHmut1p19in t are astrocytic and the majority of
IDHmut1p19qdel belong to the oligodendroglioma group
[13]. IDHwt gliomas probably constitute a genetically hetero-
geneous category of lesions, but often exhibit aggressive be-
haviour and have been suspected to represent early glioblas-
toma [14–17]. In the emerging literature on MR imaging fea-
tures of IDHwt glioma, initial lack of enhancement has been
reported in some of these tumours [6, 18, 19].
Diffusion-weighted imaging (DWI) is a technique of great
interest in cancer, because water diffusivity is impaired in
highly cellular tissues, which reflects tumour proliferative rate
and aggressiveness [20]. The phenomenon of reduced diffu-
sion preceding fulminant radiological progression of pre-
sumed LGG has been observed prior to molecular typing
[7], evoking later descriptions of IDHwt glioma serial imaging
findings [4]. Quantitative apparent diffusion coefficient
(ADC) values have demonstrated high accuracy for glioma
grading through meta-analysis [21]. For the non-invasive
identification of low to intermediate IDHwt glioma, diffusion
tensor imaging (DTI) and diffusion kurtosis imaging (DKI)
have shown potential, suggesting that reduced and heteroge-
nous diffusivity are IDHwt features [22–24]. However, ad-
vanced diffusion techniques are not universally available out-
side academic hospital institutions, may require longer scan
times and dedicated post-processing.
Mean ADC measurement could be a rapid and practicable
approach to assess glioma diffusivity, being computationally
non-demanding compared to histograms or texture analysis.
Although theoretically superior, there is no conclusive evi-
dence that whole lesion analysis outperforms region-of-
interest placement for the identification of malignant gliomas
[25].
The study presented sought to (i) investigate whether ADC
measurements from routine clinical DWI were associated with
gliomamolecular subtype and (ii) to compare the performance
of volumetric whole tumour ADC with single slice ADC
measurements.
Materials and methods
Patients
Following institutional board approval for a retrospective
study, we searched the neuropathology records revealing 37
patients with WHO grade II/III IDHwt glioma between 2009
and 2016. For comparison of the molecular groups, control
samples of IDH (IDH1-R132H) mutant gliomas (34
IDHmut1p19qint and 32 IDHmut1p19qdel) were randomly se-
lected. We sought to evaluate ADC for suspected LGG prior
to tissue diagnosis. To replicate the clinical situation, only
gliomas without gadolinium enhancement were included (2
non-enhancing gliomas were excluded because of missing
images and degraded DWI, respectively). The study sample
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consisted of 14 IDHwt (7 WHO II and 7 WHO III), 16
IDHmut1p19qint (8 WHO II and 8 WHO III) and 14
IDHmut1p19qdel (11 WHO II and 3 WHO III), amounting to
44 non-enhancing gliomas for the three molecular groups
(patient selection diagram shown in Fig. 1). No haemorrhagic
or necrotic gliomas were featured in the study.
MRI acquisition
Ours is a quaternary neurosurgical centre; therefore the stan-
dard (structural and DWI) MRI sequences in this study orig-
inated from 10 different referring institutions (institution 1 to
institution 10): 29 from our own institutions, 4 from institution
2, 3 from institution 3, 2 from institution 4, and one each from
the remaining six institutions. The studies were acquired on 18
different scanners (31 at 1.5 Tesla, and 13 at 3 Tesla) from all
major vendors: four General Electric scanners [Discovery
MR450 (number of patients n = 5), 2× Signa Excite (n = 1
each), Genesis Signa (n = 2)], seven Siemens scanners [3×
Avanto (n = 7, n = 2, n = 1), a Trio (n = 9), Symphony (n =
4), Skyra (n = 3), Espree (n = 1)], six Philips scanners [Ingenia
(n = 2), 5×Achieva (n = 1 each)] and one Toshiba scanner (n =
1). All acquisitions included axial T2-weighted images, and
axial standard 3-directional whole brain DWI. The median
[min, max] values of the parameters of the T2-weighted im-
ages were echo time (TE) = 99.5 [80, 141] ms; repetition time
(TR) = 4610 [2500, 7480] ms, in-plane resolution = 0.5 × 0.5
[0.3 × 0.3, 0.9 × 0.9] mm2; slice thickness = 5 [1, 6] mm; gap
between slices = 1.5 [0, 2] mm. All DWI acquisitions included
diffusion gradient weighting values b = 0 s/mm2 and b = 1000
s/mm2; the median [min, max] of other parameters were TE =
90.5 [69.5, 137] ms; TR = 4000 [2837, 10,000] ms, in-plane
resolution = 1.25 × 1.25 [0.5 × 0.5, 2.5 × 2.5] mm2; slice
thickness = 5 [4, 6] mm; gap between slices = 1.5 [0, 2]
mm. For each patient, the imaging study was performed on
average (standard deviation, sd) 2.3 (2.8) months prior to the
tissue diagnosis. Image examples for the glioma molecular
subgroups are shown in Fig. 2.
Post-processing and ADC analysis
ADC map calculation
In a spin echo diffusion-weighted sequence, the signal Sb [Sb =
S0 e
(−b ADC)] from each pixel in an image is formed of a first
component (S0) dependent on tissue properties (i.e. ‘spin den-
sity’, T1 and T2 relaxation times) and sequence properties (e.g.
repetition time, TR); and a second component (e−b ADC) de-
pendent on the diffusion gradients (b, in units of s/mm2) and
the apparent diffusion coefficient (ADC, in units of mm2/s).
The ADC is obtained by dividing the image acquired with-
out diffusion gradients (Sb = 0 = S0) by the image acquiredwith
diffusion gradients (Sb):
ADC ¼ 1=bð Þ ln S0=Sbð Þ ð1Þ
In this division, the dependence of ADC from S0 (and
therefore from T1, T2 and TR) is eliminated [26]. The ADC
maps were calculated using Eq. 1 and the utility fslmaths from
the software library fsl (version 5.0) [27]. Offline whole tu-
mour analysis and single slice analysis were subsequently
performed.
Fig. 1 Flow diagram of patients
included and excluded from the
analyses
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Whole tumour (volumetric) ADC analysis
Tumour volumes of interest (VOItum) were outlined by a
neuroradiology resident (S.H.) using ITK snap Toolbox
version 3.6 (www.itksnap.org [28]), covering the entire
T2 signal abnormality with each segmentation optimised
by a board-certified neuroradiologist specialised in brain
tumour imaging (S.C.T.). For multicentric gliomas, the
total volume of signal abnormality was treated as one
lesion. ADC maps were co-registered to T2 imaging using
the FLIRT toolbox [29, 30] performing a rigid body trans-
formation with a six-parameter model and ‘Normalised
Mutual Information’ as cost function. Subsequently,
ADCmean measurements were obtained for each tumour,
using the fslstats utility from fsl [25–27].
To consider possible interindividual variations in brain
diffusivity, we assessed the ADCmean in normal appearing
white matter (NAWM). For each patient, a standardised
second volume of interest (VOICS) was drawn in the con-
tralateral centrum semiovale (CS). This VOICS was used
to ca lcu la te the ADCra t i o = ADCmean (VOI t um) /
ADCmean(VOICS) (Fig. 2). For two IDH
wt tumours, the
NAWM analysis was omitted because of bilateral tumour
infiltration.
Single slice ADC analysis
Standard picture archiving and communication systems
(PACS) software (IMPAX 6.5.1.1008, Agfa-Gevaert, Mortsel,
Belgium) was used to exploit tools routinely available for
reporting of MR images. Two observers blinded to
histomolecular results (J.A.M. general radiology trainee = ob-
server 1 and S.C.T. = observer 2) located the tumour on the T2-
weighted sequence, selecting two round regions of interest on
the ADC map viewed side-by-side: The first region of interest
(ROItum) was drawn in the largest lesion cross-section sparing
the tumour margin to avoid partial volume effects. The second
round ROICS aiming for a similar size to ROItum was placed in
contralateral centrum semiovale NAWM, taking care to exclude
images with visible ventricular surfaces, cortex and/or sulcal
spaces at measurement level. Three patients were excluded
from the single slice analysis because of non-availability of an
ADC map on PACS. The ratio between the ADCmean in the
tumour and CS was calculated [PACS_ADCratio =
ADCmean(ROItum)/ADCmean(ROICS)]. No absolute ADC
values were measured by the single slice method, as their work-
station display can vary depending on the referring institution.
An example of the volumetric segmentation and single slice
ADC measurement is demonstrated in Fig. 3.
Fig. 2 WHO II/III molecular
subgroup examples showing T2-
weighted images, b1000, ADC
maps and T1-weighted post
gadolinium images of non-
enhancing a IDHwt, b
IDHmut1p19qint and c
IDHmut1p19qdel glioma
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Histopathology and molecular analysis
Paraffin blocks containing tissue were analysed at our institu-
tion’s neuropathology department according to WHO 2016
guidance and previously published data [16]. IDH R132H
immuno-negative tumours underwent multiple gene Sanger
sequencing. A quantitative polymerase chain reaction-based
copy number assay was used to determine 1p/19q status.
Statistical analysis
For the volumetric and single slice data, the statistical analysis
consisted of two steps each: (i) linear regression to assess the
association between the tumour type (IDHwt, IDHmut1p19qint,
IDHmut1p19qdel) and ADC values, followed by (ii) logistic
regression to determine if ADC values can differentiate
IDHwt from IDHmut gliomas. A receiver operating character-
istic (ROC) analysis was used to quantify the performance of
the logistic regression. For the identification of a cut-off point
for the logistic regression the ‘nearest to (0,1)’ method was
performed. Statistical significance was set at 5%. The inter-
rater agreement was expressed as an intraclass correlation co-
efficient (ICC) using a two-way random effects model. All
statistical analyses were performed using Stata version 14
(College Station, TX: StataCorp LP).
Results
The mean age was greater in the IDHwt group than in the
IDHmut groups (p = 0.0001 for IDHmut1p19qint, p = 0.005
for IDHmut1p19qdel). The larger proportion of WHO II glio-
mas in the IDHmut1p19qdel was not statistically significant
(Pearson chi-square test p = 0.115 for IDHwt and p = 0.105
for IDHmut1p19qint). The patient demographic data and tu-
mour volumes are reported in Table 1.
Association between molecular subtype and ADC
values
In the volumetric analysis, IDHwt tumours showed significantly
lower whole tumour volume ADCmean(VOItum) than
IDHmut1p19qint (p < 0.0005) and IDHmut1p19qdel (p = 0.001).
The ADCmean(VOItum) in the IDH
mut1p19qint group was signif-
icantly higher than in the IDHmut1p19qdel group (p = 0.0047).
IDHwt gliomas had a significantly lower whole tumour
ADCra t i o than IDH
mut1p19qin t (p < 0.0005) and
IDHmut1p19qdel (p = 0.019). The ADCrat io in the
IDHmut1p19qint group was significantly higher than in the
IDHmut1p19qdel group (p = 0.0054).
On single slice assessment, a significantly lower mean
PACS_ADCrat io was observed for IDH
wt than for
Fig. 3 Image examples
demonstrating the whole lesion
volumetric segmentation (mask
overlaid on right frontal
IDHmut1p19qint glioma), single
slice largest tumour cross-section
ROItum and comparative
contralateral NAWM ROICS
placements
Table 1 Patient demographic data and tumour volumes
Whole tumour ADCmean (VOItum)
Patient group Nr of patients
total (male)
Age in years
(mean ± sd) (years)
Tumour volume
(mean ± sd) (cm3)
CS NAWM volume
(mean ± sd) (cm3)
Tumour volume for patients
with bilateral infiltration
(mean ± sd) (cm3)
IDHwt 14 (9) 53 (± 14) 64 (± 68) (n = 12) 11.6 (± 2.5) (n = 12) 366 (± 46) (n = 2)
IDHmut1p19int 16 (6) 33.9 (± 8.6) 60 (± 44) 10.9 (± 2.3) N/A
IDHmut1p19del 14 (7) 38.9 (± 8.3) 48 (± 50) 10.8 (± 2.5) N/A
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IDHmut1p19qint (p < 0.0005 observer 1; p < 0.0005 observer
2) and for IDHmut1p19qdel (p = 0.001 observer 1; p = 0.001
observer 2). The PACS_ADCratio in the IDH
mut1p19qint group
was higher than in the IDHmut1p19qdel group (p = 0.0008 for
observer 1 and p = 0.0025 for observer 2). No statistical asso-
ciations were demonstrated between the NAWM ADCmean
values and molecular subtype.
The intra-rater agreement for the PACS_ADCratio mea-
surements was very high: the correlation of measurements
made on the same individual was 0.96, while the correla-
tion between mean observer ratings was 0.98. The correla-
tion of measurements equaled the consistency agreement,
indicating no systematic difference between the two ob-
servers. The single slice ADCratio values were slightly but
systematically higher than the volumetric ADCratio. The
numerical results of the association between tumour type
and ADC values for the volumetric and single slice analy-
ses are reported in Table 2. In Table 3, the difference be-
tween the ADC values in IDHmut1p19qin t and in
IDHmut1p19qdel is shown. In Table 4 the ICC values are
detailed. The boxplots of the ADCmean and ADCratio values
are depicted in Fig. 4.
Diagnostic performance of ADC values
For ADCmean(VOItum), a ROC analysis quantified the accuracy
of correctly classifying tumour type to an area under the curve
(AUC) of 0.94. The cut-off point for the ADCmean(VOItum) was
1201 × 10−6 mm2/s, with a sensitivity of 0.83 and a specificity
of 0.86. For a decrease in the ADCmean(VOItum) value by 1.0 ×
10−5 mm2/s, the odds of IDHwt increased by 78% (p = 0.003).
For the volumetric ADCratio, the ROC analysis yielded an
AUC of 0.90 with a sensitivity of 0.80 and a specificity of
0.92 for a threshold ADCratio of 1.65. For a decrease in the
volumetric ADCratio value by 0.1, the odds of IDH
wt increased
by 46% (p = 0.004).
Table 2 Results of the linear regression between ADC and tumour type (IDHwt is the reference group)
Whole tumour ADCmean (VOItum)
Patient group ADCmean(VOItum)
mean (sd)
(10−6 mm2/s)
Regression
coefficient
(10−6 mm2/s)
95% CI of the
regr. coeff.
(10−6 mm2/s)
p
IDHwt 1032 (168) 1032 922–1141 0.0005
IDHmut1p19int 1543 (254) 511 361–661 0.0005
IDHmut1p19del 1321 (162) 289 134–444 0.001
Whole tumour ADCratio
Patient group ADCratio
mean (sd)
Regression
coefficient
95% CI of the
regr. coeff.
p
IDHwt 1.49 (0.32) 1.49 1.32–1.66 0.0005
IDHmut1p19int 2.09 (0.34) 0.59 0.37–0.82 0.0005
IDHmut1p19del 1.77 (0.20) 0.28 0.05–0.51 0.019
Single slice PACS_ADCratio first observer
Patient group PACS_ADCratio
mean (sd)
Regression
coefficient
95% CI of the
regr. coeff.
p
IDHwt 1.50 (0.21) 1.50 1.33–1.68 0.0005
IDHmut1p19int 2.37 (0.35) 0.87 0.63–1.10 0.0005
IDHmut1p19del 1.96 (0.27) 0.45 0.20–0.70 0.001
Single slice PACS_ADCratio second observer
Patient group PACS_ADCratio
mean (sd)
Regression
coefficient
95% CI of the
regr. coeff.
p
IDHwt 1.48 (0.19) 1.48 1.28–1.68 0.0005
IDHmut1p19int 2.37 (0.38) 0.88 0.62–1.14 0.0005
IDHmut1p19del 1.96 (0.36) 0.47 0.20–0.75 0.001
Regression coefficient represents the difference in the dependent variable (ADC) between each of the two IDHmut groups and the reference group
(IDHwt )
Table 3 F test for the difference between IDHmut1p19int and
IDHmut1p19del
Analysis type p
ADCmean (VOItum) 0.0047
Whole tumour ADCratio 0.0054
PACS_ADCratio 1st observer 0.0008
PACS_ADCratio 2nd observer 0.0025
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A ROC analysis quantified the accuracy of the
PACS_ADCratio logistic regression in correctly classifying tu-
mour type to an AUC of 0.96 for observer 1 and 0.95 for
observer 2. The cut-off point for the PACS_ADCratio for ob-
server 1 (observer 2) was 1.83 (1.76) with a sensitivity of 0.80
(0.86) and a specificity of 1.00 (0.91) at the cut-off point. For a
decrease in the single slice ADCratio value by 0.1, the odds of
IDHwt increased by 62% (p = 0.005) for observer 1 and 57%
(p = 0.004) for observer 2. The numerical results for glioma
subtype prediction are reported in Table 5. The ROC curves
are depicted in Fig. 5.
Discussion
In this analysis, we observed that ADC values obtained from
standard clinical DWI are a highly significant predictor of
non-enhancing glioma IDH status and may permit non-
invasive molecular subtyping in accordance with the 2016
WHO classification.
Two recent surveys highlighted clinical practices in caring
for patients with presumed LGG, with approximately 50% of
neurosurgeons adopting a ‘wait and see’ approach balanced
against surgical risk [31], and only 21% performing an upfront
biopsy [32]. Consequently, innocuous appearing IDHwt glio-
mas may reveal their aggressive nature through progression
and receive treatment with a delay.
Low ADC values are associated with increased glioma cel-
lularity and worse prognosis, supported by comparisons of dif-
fusivity, histological specimens and clinical data in multiple
studies [5, 33–37]. Low diffusivity predicts poor astrocytoma
survival independent fromWHO grade [38], although no linear
relation exists between ADC and glioma prognosis [39].
Past studies to distinguish astrocytoma and oligodendroglioma
using ADC values yielded variable success [40, 41], and in ret-
rospect may have been influenced by the incomplete overlap
between histological and molecular groups. Diagnostic focus
has shifted to genetic typing, yet immunohistochemistry tests
are complex and not infallible, requiring interpretation in in the
context of morphological criteria and test type performed to avoid
interpretational errors [42].
Table 4 Inter-rater agreement expressed as intraclass correlation
coefficient (ICC)
Correlation ICC
(95% CI)
Consistency ICC
(95% CI)
Observer 1 vs observer 2 - PACS_ADCratio
Individual ICC 0.96 (0.92–0.98) 0.96 (0.92–0.98)
Average ICC 0.98 (0.96–0.99) 0.98 (0.96–0.99)
Observer 1 PACS_ADCratio vs volumetric ADCratio
Individual ICC 0.80 (0.35–0.92) 0.87 (0.77–0.93)
Average ICC 0.89 (0.52–0.96) 0.93 (0.87–0.96)
Observer 2 PACS_ADCratio vs volumetric ADCratio
Individual ICC 0.79 (0.43–0.91) 0.85 (0.74–0.92)
Average ICC 0.88 (0.60–0.95) 0.92 (0.85–0.96)
Fig. 4 Boxplot of the values of
the a whole tumour
ADCmean(VOItum), b whole
tumour ADCratio, c single slice
PACS_ADCratio first observer and
d single slice PACS_ADCratio
first observer
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Recently, Leu et al. were able to assign gliomas to the WHO
2016 molecular groups using ADC; however, their method dif-
fered fromours by including enhancing lesions andADCmedian
values derived from b700–1000 gradients with DTI analysed for
some patients [43]. To our best knowledge, this is the first IDH
typing study to focus on non-enhancing gliomas, using b1000
values derived from 3-directional DWI. This is particularly im-
portant, as such tumours are usually assumed to be less aggres-
sive in common clinical practice.
We found ADCratio values to be closely reproducible when
comparingwhole lesionmeasurements against single slice region
of interest placements, for which there was near complete inter-
observer agreement. The similarity of our volumetric and single
slice results could be explained by a relative homogeneity of
these non-enhancing, non-necrotic gliomas. Both the absolute
ADCmean values and ADCratio appear valuable for this lesion
type. The quicker and easier single slice analysis even performed
marginally better. This is in line with results of previous imaging
research, which suggested that whole lesion diffusivity measure-
ment is not always superior to ROI analysis [25, 44].
The ability of ADC to predict glioma subtypes and optimum
thresholds may be subject to ROI placement technique with pre-
vious research focusing on minimum ADC value analysis: Xing
et al. showed a statistical correlation between ADC and IDH
status using a multiple (≥ 5) ROI technique with the mean of
the lowest ADCmeasurement chosen as minimumADC in con-
sensus [45]. In a similar fashion, a previous DTI study for IDH
typing used multiple ROI placements and a two-reader consen-
sus method to obtain minimum ADC values [24].
As a reference ROI, we chose the centrum semiovale for its
potentially greater reproducibility compared to a ‘mirror’ ROI
[45], because this could be influenced by tumour location. We
Table 5 Cut-off point estimation
Method Cut-off point Sensitivity at cut-off point Specificity at cut-off point AUC at cut-off point
ADCmean(VOItum) 1201
(10−6 mm2/s)
0.83 0.86 0.85
Whole tumour ADCratio 1.65 0.80 0.92 0.86
PACS_ADCratio 1st observer 1.83 0.86 1.00 0.93
PACS_ADCratio 2nd observer 1.76 0.86 0.91 0.88
Fig. 5 ROC curves for the a whole tumour ADCmean(VOItum), b whole tumour ADCratio, c single slice PACS_ADCratio observer 1 and d observer 2
Eur Radiol
avoided the internal capsule [24], which is a smaller structure
and more difficult to locate by an untrained rater.
Lee et al. found ADCmean and ADC histograms useful for
IDH typing of WHO grade III and IV gliomas [46]. However,
for glioblastoma IDH typing alone, a recent study identified
no difference in ADC values [47]. In Tan et al.’s study of grade
II–IV gliomas, the accuracy of ADC for IDH typing decreased
with higher grade, which may reflect greater lesion heteroge-
neity [24]. It is probable that in such circumstances advanced
diffusion acquisitions (e.g. DKI or multi-b-value imaging)
could provide greater tissue microstructural information.
The good performance of the single slice ROI technique in
IDH typing of non-enhancing lower grade gliomas was unex-
pected, but is highly relevant. It implies that such easy-to-
perform measurements could be incorporated into clinical re-
ports, complementing advanced MR modalities such as perfu-
sion and 2HG spectroscopy [48, 49] pending tissue diagnosis.
The origin of data from 18 MRI systems could represent a lim-
itation of this study, but reflects clinical reality. The fact that
significant separation of glioma subtypes could be obtained from
this dataset further underscores the robustness of ADC.
It remains unknown why intermediate ADC values were
observed in the 1p19q co-deleted gliomas, despite their best
prognosis. This result is consistent with published data on
intermediate diffusivity in oligodendroglioma; interestingly
this tumour subtype may also mimic malignant gliomas on
MR perfusion studies [39, 50].
In summary, the results from this study suggest that for
newly diagnosed non-enhancing gliomas with ADC ratio
values of 1.8 or less, further investigation with consideration
of early tissue diagnosis is advisable given an increased risk of
IDHwt molecular status.
Conclusions
ADCmeasurement appears to be a simple and powerful meth-
od for molecular subtyping of non-enhancing WHO II–III
gliomas, specifically to identify IDHwt neoplasms. In our pa-
tient cohort, a two-dimensional ROI measurement in the larg-
est lesion cross-section appeared representative of the entire
tumour with comparable results.
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